Articles related to GYNECOLOGICAL CANCERS

In a phase 3 trial, tisotumab vedotin showed a median overall survival of 11.5 months compared to 9.5 months with standard chemotherapy in patients with recurrent cervical cancer, representing a 30% reduction in the risk of death.

Dr. Larissa H. Mattei’s personal account offers a rare glimpse into the emotional and professional challenges faced by healthcare providers who find themselves on both sides of a cancer diagnosis.

A 51-year-old woman’s case of Meigs’ syndrome underscores the importance of distinguishing this benign condition from ovarian cancer, emphasizing the resolution of symptoms following the excision of the ovarian fibroma.

Virginia Commonwealth University’s latest research introduces a novel, urine-based test for ovarian cancer, utilizing nanotechnology to identify specific peptides, offering a new avenue for early detection and enhancing patient care strategies.

The recent study on bevacizumab’s effect on ovarian cancer progression provides valuable insights into its initial benefits and subsequent risks.

Join historian Susan W. Wade, Ph.D., in exploring her personal experience with vulvar cancer and participation in an experimental clinical trial. Wade’s firsthand account offers not only medical insights but a deeper understanding of the patient’s psychological journey and a reflection on the future of oncology treatments.